{"filings":[{"id":1177038,"accession_number":"0001493152-26-029486","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-06-22T11:30:26+00:00","items":["5.07"],"status":"ready","headline":"Harrow annual meeting elects four directors, approves say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four directors elected: Mark Baum, Adrienne Graves, Lauren Silvernail, Perry Sternberg; broker non-votes 8,867,198.","Say-on-pay advisory approved: 18,065,856 for, 2,395,240 against, 502,679 abstentions.","Ratified Deloitte & Touche as auditor for FY2026: 28,578,182 for, 1,249,248 against, 3,543 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":816996,"accession_number":"0001493152-26-026983","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-06-03T13:15:27+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harrow furnishes corporate presentation for investor meetings; no material new info","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed a corporate presentation dated June 2026 under Regulation FD.","Presentation may be used at investor conferences and meetings.","No earnings, financial results, or material events disclosed in the filing.","No changes to guidance, leadership, or business strategy provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13087,"accession_number":"0001493152-26-022227","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-05-11T20:10:43+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harrow Q1 revenue $44.2M, net loss $27.6M; VEVYE market share reaches 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $44.2M, down 8% YoY, including ~$8M non-recurring gross-to-net adjustment related to new VEVYE commercial coverage.","Net loss of $27.6M ($0.74 diluted EPS) vs. loss of $17.8M ($0.50) in Q1 2025; Adjusted EBITDA -$12.7M.","VEVYE delivered record quarterly prescriptions: NRx +25% QoQ, TRx +11% QoQ; surpassed XIIDRA on monthly TRx with ~14% market share.","IHEEZO unit demand +18% YoY to 45,509 units (82% from retina); TRIESENCE unit demand +136% YoY for 6th consecutive growth quarter.","Q2 2026 revenue guidance $71M-$81M; full-year 2026 revenue reaffirmed $350M-$365M, Adjusted EBITDA $80M-$100M."],"consensus_eps_estimate":-0.4095,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":44203000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103241,"accession_number":"0001493152-26-013199","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Harrow issues $50M additional 8.625% Senior Notes due 2030; net proceeds ~$48.7M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $50M aggregate principal amount of 8.625% Senior Notes due 2030, additional to $250M existing notes.","Net proceeds after discounts and expenses were approximately $48.7 million.","Notes rank equally with existing notes; same maturity (2030) and coupon (8.625%).","Proceeds to be used for general corporate purposes, including growth initiatives, product launches, and strategic opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103240,"accession_number":"0001493152-26-012389","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Harrow prices $50M add-on of 8.625% senior notes due 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $50.0M aggregate principal of 8.625% senior unsecured notes due 2030 in private offering.","Notes issued as additional series under existing indenture with $250M notes from Sept 2025; same terms.","Issue price 100.25% of principal plus accrued interest from March 15, 2026; closing expected March 27, 2026.","Net proceeds for general corporate purposes including growth initiatives, product development, and strategic opportunities.","Interest payable semi-annually on March 15 and September 15; first payment Sept 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103239,"accession_number":"0001493152-26-012279","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Harrow launches $50M add-on of 8.625% Senior Notes due 2030 for growth","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Harrow announces private offering of $50M in additional 8.625% Senior Notes due 2030.","New notes will be issued under same indenture as existing $250M notes from Sept 2025, treated as a single series.","Proceeds used for general corporate purposes, including new product launches, R&D, and strategic opportunities.","Offer limited to QIBs in the US and non-US persons in offshore transactions under Regulation S.","Notes are senior unsecured obligations, guaranteed by certain domestic subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103238,"accession_number":"0001493152-26-009452","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harrow furnishes March 2026 corporate presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished under Regulation FD; no material financial updates or guidance changes provided.","Management may use the presentation at investor conferences and meetings.","No new operational metrics, revenue, or earnings data included in the filing.","Investors should rely on prior public disclosures for current performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103237,"accession_number":"0001493152-26-008552","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harrow posts Q4 record revenue $89.1M, net income $6.6M; guides 2026 revenue $350-$365M, EBITDA $80-$100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $89.1M record (+33% YoY); full-year 2025 revenue $272.3M (+36%).","GAAP net income $6.6M in Q4; FY25 net loss $5.1M; Adj. EBITDA $24.2M Q4, $61.9M FY.","Operating cash flow $43.9M in FY25 vs -$22.2M in 2024; cash $72.9M.","2026 guidance: revenue $350-$365M, Adj. EBITDA $80-$100M; CEO plans to double VEVYE salesforce, expand IHEEZO in-office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103236,"accession_number":"0001493152-26-004635","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Harrow reaffirms 2025 revenue guidance of $270-280M, promotes Sullivan to CCO, settles CA regulatory matters","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reaffirmed FY2025 revenue guidance of $270-280 million; full-year results expected in early March.","Patrick Sullivan promoted to CCO; $425k base salary, 40% target bonus, 40,000 RSUs vesting on $230M quarterly branded revenue.","VEVYE sales force to double to ~100 territories by Memorial Day; TRIESENCE surgical sales force also doubling.","ImprimisRx settled with CA Board of Pharmacy for ~$157k fine and voluntarily exited CA market; not financially material.","MELT-300 NDA submission on track for H1 2027; MELT-210 NDA on track."],"consensus_eps_estimate":0.3761,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":272303000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119487,"accession_number":"0001493152-25-023988","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.01","3.02","8.01","9.01"],"status":"ready","headline":"Harrow completes Melt acquisition for ~$4.3M cash; outlines MELT-300 NDA timeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid ~$4.3M cash at closing for remaining Melt equity; contingent milestone payments unchanged.","Acquires Melt pipeline: MELT-300 (Phase 3, SPA), MELT-210, MELT-400; expands into procedural sedation.","Next steps for MELT-300: PK studies, NDA submission H1 2027, potential approval H1 2028, launch H2 2028.","MELT-300 is a sublingual midazolam/ketamine formulation; could be first FDA-approved non-opioid non-IV sedation.","Integration of Melt into Harrow's operations; leveraging MKO Melt network for commercial readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119486,"accession_number":"0001493152-25-021555","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harrow Q3 revenue $71.6M (+45% YoY), net income $1.0M; VEVYE revenue $22.6M (+22% QoQ)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.6M (+45% YoY); GAAP net income $1.0M vs loss $4.2M YoY; Adj. EBITDA $22.7M vs $8.8M","VEVYE revenue $22.6M (+22% QoQ); national DED market share 10.5% (up 2.7pp); coverage agreements with largest PBM effective Jan 2026","IHEEZO revenue $21.9M (+70% YoY); on track to exceed $50M annual revenue by year-end 2025","Agreed to acquire Melt Pharmaceuticals (MELT-300) for non-opioid sedation; refinancing cut interest ~$3M/yr, added $50M liquidity"],"consensus_eps_estimate":0.2687,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":183211000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119485,"accession_number":"0001493152-25-017007","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ImprimisRx (Harrow subsidiary) appoints Frank Mullery as CEO; prior CEO John Saharek transitions out","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Saharek ceased as President/CEO of ImprimisRx effective Oct 6, 2025; transitions to non-officer role with no new compensation.","Frank Mullery appointed CEO of ImprimisRx; previously President of Sintetica US and led Mylan Institutional to >$1B revenue.","Bridseida Cruz appointed Head of Quality; over 25 years experience in FDA remediation and operational improvement.","No compensatory arrangements entered with Saharek in connection with transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119484,"accession_number":"0001493152-25-016473","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K/A","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Harrow to acquire Melt Pharmaceuticals for $0.50/share; already owns 45%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Harrow will pay $0.50 per share of Melt Common Stock for the remaining ~55% it does not already own.","Melt is a clinical-stage company developing MELT-300 for procedural sedation in cataract surgery.","Transaction approved by special committees of both boards, each receiving fairness opinions.","Harrow and Melt entered a Milestone Payment Agreement tied to regulatory and sales milestones.","Merger Sub will merge with and into Melt; Melt will survive as wholly owned subsidiary of Harrow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136056,"accession_number":"0001493152-25-015878","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Harrow enters $40M senior secured revolving credit facility with Fifth Third Bank","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $40M revolving credit facility with uncommitted incremental $20M line available.","Facility matures Sept 26, 2030 or 91 days before earliest 8.625% senior notes due 2030.","Interest options: base rate + 0.25%-0.75% or SOFR + 1.25%-1.75%; unused fee 0.25%.","Secured by first-priority lien on substantially all assets of Harrow and its guarantors.","Financial covenant requires fixed charge coverage ratio of at least 1.10x monthly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136055,"accession_number":"0001493152-25-015712","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harrow holds Investor Day on Sept 26, 2025; presentation furnished","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company hosted Investor Day and furnished presentation as Exhibit 99.1.","No specific financial or operational details provided in this filing.","Presentation used at event and subsequent investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136054,"accession_number":"0001493152-25-015054","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Harrow signs definitive deal to acquire Melt Pharma for initial $4.3M plus milestones up to ~$352.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Initial cash payment of ~$4.3M for remaining 55% equity; contingent $87.2M upon FDA approval of MELT-300.","Upon CMS J-Code assignment, Harrow will issue ~1.112M shares of common stock.","Additional cash payments up to ~$261M based on annual net sales milestones ($100M–$1B).","Harrow plans NDA submission in 2027, potential US launch in 2028 for MELT-300 sublingual sedation.","Deal approved by independent committee; fairness opinion from Lake Street Capital Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136053,"accession_number":"0001493152-25-014242","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Harrow dismisses Crowe LLP, appoints Deloitte & Touche as new independent auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Crowe dismissed as auditor effective Sept 17, 2025; no adverse opinions or disagreements during their tenure covering FY2024.","Audit Committee approved Deloitte to audit FY2025 financials, subject to client acceptance procedures and engagement letter execution.","Crowe's letter agreeing with disclosures filed as Exhibit 16 to this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136052,"accession_number":"0001493152-25-013268","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Harrow issues $250M 8.625% senior notes due 2030; redeems 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250M aggregate principal of 8.625% senior notes due 2030; net proceeds ~$244M.","Proceeds to repay Oaktree credit facility borrowings and redeem outstanding 2026 and 2027 notes.","Delivered notice to redeem all 2026 notes on October 13, 2025 at 100% plus make-whole premium.","Interest payable semi-annually starting March 15, 2026; notes mature September 15, 2030.","Notes are senior unsecured and guaranteed by existing and future domestic restricted subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136051,"accession_number":"0001493152-25-012840","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Harrow prices $250M 8.625% notes due 2030; proceeds to repay $107.5M Oaktree facility and redeem 2026/2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$250M 8.625% senior unsecured notes due 2030 priced at par; interest semi-annual starting March 15, 2026.","Proceeds to repay $107.5M Oaktree facility, redeem $75M 8.625% 2026 notes and $40.25M 11.875% 2027 notes.","Closing expected September 12, 2025, subject to customary conditions; guaranteed by certain domestic restricted subsidiaries.","Remaining proceeds for general corporate purposes, including potential business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136050,"accession_number":"0001493152-25-012778","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["1.01","8.01","2.03","9.01"],"status":"ready","headline":"Harrow launches $250M senior notes offering, enters $40M revolver, and discloses Melt Pharmaceuticals acquisition plan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Launched $250M offering of senior unsecured notes due 2030 to refinance existing debt, including redemption of 2026 Notes (8.625%, $75M) and 2027 Notes (11.875%, $40.25M).","Entered commitment for $40M revolving credit facility with Fifth Third Bank, secured by substantially all assets, maturing 91 days before 2030 Notes maturity or five years from closing.","Issued conditional notice to redeem all $40.25M 2027 Notes at 102% of par plus accrued interest on Oct 9, 2025, contingent on completion of the Offering.","Plans to redeem $75M 2026 Notes at 100% plus make-whole, and repay $107.5M Oaktree loan, with remaining proceeds for general corporate purposes.","Disclosed non-binding LOI to acquire remaining 55% of Melt Pharmaceuticals for ~$4.3M cash at close plus contingent milestones; CEO and CFO hold Melt interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136049,"accession_number":"0001641172-25-025336","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Harrow appoints Andrew R. Boll as President; names Randall E. Pollard as CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew R. Boll appointed President effective Aug 21, 2025, while continuing as CFO and Secretary; no compensation change.","Randall E. Pollard appointed Chief Accounting Officer effective Sept 1, 2025; will report to Boll.","Pollard receives $400K base salary, 40% target cash bonus, and relocation expenses.","Amended bylaws designate CEO as principal executive officer and clarify officer roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136048,"accession_number":"0001641172-25-022971","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harrow Q2 revenue $63.7M (+30% YoY); net income $5M; VEVYE on track for >$100M; adds Samsung Bioepis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $63.7M, up 30% YoY; GAAP net income $5.0M vs loss of $6.5M; Adj EBITDA $17.0M (up from $8.8M).","VEVYE dry eye revenue on track to exceed $100M in 2025; Q2 market share 7.8%; 66% sequential prescription growth.","IHEEZO revenue $18.3M (+62% YoY, +251% QoQ); TRIESENCE added 870 new accounts YTD; unit growth 32% QoQ.","Secured exclusive U.S. rights to Samsung Bioepis ophthalmic biosimilars (BYOOVIZ, OPUVIZ) in July 2025.","Acquired U.S. rights for BYQLOVI (clobetasol) in June 2025; Apollo Care alliance to expand VEVYE access."],"consensus_eps_estimate":0.0074,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":111573000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136047,"accession_number":"0001641172-25-019976","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Harrow secures exclusive U.S. rights to two ophthalmology biosimilars from Samsung Bioepis","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Gains exclusive U.S. commercial rights to BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), FDA-approved biosimilars of Lucentis and Eylea.","Consideration includes one-time upfront payment, net-sales milestone payments, and a share of U.S. net sales (amounts not disclosed).","Transition of commercial rights from Biogen to Samsung expected by end of 2025; Harrow will then assume full commercialization.","U.S. retinal disease treatment market valued at ~$9B; products target Wet AMD, Macular Edema, DME, and Diabetic Retinopathy.","CEO Mark Baum calls the acquisition transformational, reinforcing Harrow's commitment to affordable alternatives in eyecare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153085,"accession_number":"0001641172-25-015665","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harrow holds 2025 annual meeting; all proposals approved by stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four directors elected: Mark L. Baum, Adrienne L. Graves, Lauren P. Silvernail, Perry J. Sternberg.","Harrow 2025 Incentive Stock and Awards Plan approved with 21.7M for vs 1.77M against.","Crowe LLP ratified as auditor for FY2025 (31.2M for, 23K against).","Say-on-pay approved on advisory basis (22.5M for) and frequency set to one year (20.4M for).","31.3M shares voted of 36.7M outstanding; broker non-votes recorded on director and incentive plan items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153084,"accession_number":"0001641172-25-014234","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Harrow licenses exclusive U.S. rights to BYQLOVI ophthalmic steroid from Formosa","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $500,000 at first commercial sale; additional milestone payments and royalties on gross profits.","BYQLOVI is first new ophthalmic steroid class in over 15 years; FDA-approved for post-op inflammation/pain.","Expected launch in Q4 2025; U.S. market exceeds 7M annual ophthalmic surgeries.","Clinical data: 77-85% pain-free at Day 4; 1.4% elevated IOP; BID dosing 14 days without loading/maintenance.","Formulated with Formosa's proprietary APNT nanoparticle technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153083,"accession_number":"0001641172-25-009247","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow Q1 revenue $47.8M (+38% YoY); VEVYE revenue $21.5M (+35% QoQ); reaffirms >$280M FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $47.8M, up 38% YoY; GAAP net loss $(17.8)M; adjusted EBITDA $(2.0)M.","VEVYE revenue $21.5M (+35% QoQ); VAFA launch drove new RXs >4X and prescribers >4X at PhilRx.","VEVYE new patent exp. 2042 added to Orange Book; second production site expected H1 2026.","TRIESENCE received CMS pass-through status Apr 1; accounts ordering more than doubled since Jan.","Refinancing $222.75M debt in active discussions; expect resolution by late summer/early fall."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":47831000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171869,"accession_number":"0001641172-25-000915","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow Q4 revenue $66.8M (+84% YoY), net income $6.8M; FY2025 guidance >$280M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $66.8M (+84% YoY); FY2024 revenue $199.6M (+53% YoY).","GAAP net income Q4 $6.8M vs loss $9.1M; Adjusted EBITDA Q4 $22.5M vs $2.6M.","IHEEZO unit demand +43% QoQ to 49,130 units; VEVYE prescriptions +44% QoQ, approaching 5% DED market share.","TRIESENCE awarded CMS transitional pass-through (April 2025-2028); five-year supply agreement with CMO; next-gen NDA by 2027.","FY2025 revenue guidance 'over $280M' (>40% YoY); cash $47.2M; met leverage ratio, avoided warrant issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171868,"accession_number":"0001493152-25-010589","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow reports preliminary Q4 revenue $65-67M, FY ~$199M; 2025 guidance >$280M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue $65-67M; full-year revenue $198-200M, both records.","Q4 net income $5-7M; full-year net loss $(17-19)M; adjusted EBITDA Q4 $21-23M, FY $39-41M.","2025 revenue guidance of \"over $280 million\", driven by higher-margin branded business.","Met annual leverage ratio under senior secured loan, avoiding warrant issuance to lenders.","Audited results and 10-K filing delayed; company cites auditor needing extra time, no accounting disagreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171867,"accession_number":"0001493152-25-002913","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Marty A. Makary resigns from Harrow Board; Board size reduced to four","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Makary's resignation effective Jan 19, 2025; no disagreement with company operations.","Board reduced size from five to four members on Jan 19.","Makary served as director; resignation is not due to policy or practice disputes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188866,"accession_number":"0001493152-24-045283","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow Q3 revenue up 44% to $49.3M; reaffirms FY2024 guidance above $180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $4.2M; Adjusted EBITDA $8.8M; core gross margin improved to 80%.","VEVYE prescriptions up 55% QoQ; IHEEZO unit demand up 15% QoQ; TRIESENCE relaunched in October.","Cash $72.6M; $37M milestone payment for TRIESENCE funded by $30M Oaktree drawdown.","First major Medicare Part D win for VEVYE with Express Scripts, Cigna, Kaiser, CVS Caremark.","FY2024 revenue guidance reaffirmed at >$180M; Q4 expected to significantly outpace Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":132783000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188865,"accession_number":"0001493152-24-042600","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Harrow draws $30M under Oaktree loan for Novartis Triescence milestone; amends credit terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $30M on Oct 25, 2024, under Oaktree Loan to partially fund $37M milestone to Novartis for Triescence commercial availability.","Total drawn under Oaktree Loan now $107.5M; no additional borrowing capacity remains.","Oaktree waived make-whole costs on the $30M draw if repaid before March 31, 2025.","Second Amendment excludes the $30M draw from Total Leverage Ratio calculation.","Milestone payment for Triescence was made on October 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205342,"accession_number":"0001493152-24-035390","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harrow files 8-K with corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation attached for investor conferences; no new financial figures or material events disclosed in the filing.","The filing is a routine Regulation FD disclosure without substantive updates on operations, earnings, or guidance.","No specific numbers or events from the presentation are provided in the 8-K or exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205341,"accession_number":"0001493152-24-030563","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow Q2 2024 record revenue $48.9M (+46% YoY); adj EBITDA $8.8M; guides FY rev >$180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $48.9M, up 46% YoY and 42% sequentially; GAAP net loss $(6.5)M.","Adjusted EBITDA $8.8M; core gross margin 79% (up from 78%).","IHEEZO unit demand up 98% QoQ; VEVYE prescriptions up 212% QoQ; new IHEEZO supply agreements.","FY2024 revenue guidance >$180M (excluding TRIESENCE); expects back-half outperformance.","TRIESENCE PPQ Batch 2 passes initial tests; third batch scheduled; potential 2024 relaunch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":83526000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222236,"accession_number":"0001493152-24-025198","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Harrow replaces auditor KMJ with Crowe after KMJ partners and staff join Crowe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KMJ Corbin & Company resigned as independent auditor on June 24, 2024, after its partners/staff joined Crowe LLP.","Audit Committee appointed Crowe LLP as new independent registered public accounting firm effective June 25, 2024.","KMJ's reports for fiscal years 2022 and 2023 contained no adverse opinion or modification.","No disagreements or reportable events occurred between the company and KMJ during the past two fiscal years or subsequent interim period.","KMJ provided a letter agreeing with the company's statements, filed as Exhibit 16."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222235,"accession_number":"0001493152-24-024111","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harrow shareholders reelect all five directors, ratify auditor, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with majority support; broker non-votes ~9.96M.","KMJ Corbin & Company ratified as auditor for FY2024 with 26.5M votes for, 121K against.","Advisory vote on executive compensation approved with 14.9M for, 1.7M against.","Total shares voted: 26,681,036 of 35,381,611 eligible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222234,"accession_number":"0001493152-24-018898","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow Q1 revenue up 33% to $34.6M; net loss widens; FY2024 guidance at least $180M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $34.6M (+33% YoY); GAAP net loss $(13.6M) vs $(6.6M) prior year; adj. EBITDA $0.2M vs $5.3M.","Reaffirms FY2024 revenue guidance of at least $180M, expecting growth with back half stronger.","VEVYE covered lives exceed 150M (from 40M); IHEEZO CMS separate reimbursement confirmed retroactive to Jan 1, 2024.","Signed IHEEZO supply agreements with 7 multi-practice accounts; new patent through 2039. TRIESENCE PPQ batch passing preliminary assays.","Appointed Greg DiPasquale as SVP, Head of Commercial (from Regeneron). Sold Eton shares for $5.5M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":34587000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241759,"accession_number":"0001493152-24-010740","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CMS increases MUE for Harrow's IHEEZO J-Code from 1 to 2, effective July 2024 retroactive to Jan 1, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS approved increase of Medically Unlikely Edit (MUE) for IHEEZO J-Code J2403 from 1 to 2 units.","Change allows billing for two vials of IHEEZO, supporting bilateral ocular procedures.","Effective July 2024, with retroactive application to procedures from January 1, 2024.","Company requested the change in February 2024 citing ophthalmologist need for bilateral use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241758,"accession_number":"0001493152-24-010600","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Harrow gets CMS confirmation that IHEEZO is separately payable in physician office setting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS confirmed IHEEZO's J-Code 2403 will be included in April 2024 quarterly ASP drug pricing file.","Separate payment for IHEEZO in physician offices applies under Medicare Part B beginning April 2024.","This regulatory milestone may improve IHEEZO adoption and reimbursement for Harrow (HROW)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241757,"accession_number":"0001493152-24-010520","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harrow full-year 2023 revenue $130.2M (+47% YoY), GAAP net loss widens to $24.4M; adj EBITDA $28.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $130.2M, up 47% YoY; GAAP net loss $24.4M (vs $14.1M loss in 2022).","Adjusted EBITDA $28.1M, +116% YoY; cash from ops $3.8M full-year, $8.7M in Q4.","IHEEZO Q4 reorder rate 83%; Q1 2024 sales impacted by Change Healthcare cyberattack; CMS added J-code to ASP file.","VEVYE launch exceeding expectations; 70% refill rate; over 40M covered lives including TriCare and Aetna.","TRIESENCE first PPQ batch scheduled for April 15; NDA transferred; price set at $944/unit; targeting 90K units inventory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241756,"accession_number":"0001493152-24-006873","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Harrow licenses Canadian rights to five ophthalmic products to Apotex; eligible for milestone payments and royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Apotex gets exclusive Canadian rights to VERKAZIA and Cationorm PLUS; will pursue approval for VEVYE, IHEEZO, and ZERVIATE.","Harrow eligible for milestone payments tied to manufacturing, regulatory approval, and commercial milestones plus royalties on net sales.","Apotex is Canada's largest pharmaceutical company, with a track record in eyecare.","Deal covers both prescription (VERKAZIA) and OTC (Cationorm PLUS) products, expanding Harrow's reach into Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241755,"accession_number":"0001493152-24-004161","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Harrow expands board to six members, appoints Dr. Adrienne Graves and Lauren Silvernail","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 4 to 6 members effective January 26, 2024.","Dr. Adrienne Graves brings ophthalmology expertise as former CEO of Santen Inc. and board member at multiple eye-care firms.","Lauren Silvernail brings financial and strategic expertise as former CFO of Evolus, Revance, and ISTA Pharmaceuticals.","Appointments are effective immediately; press release issued January 29, 2024.","Neither new director has been assigned to a board committee at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241754,"accession_number":"0001493152-24-000192","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["1.02","8.01","5.02","5.05","9.01"],"status":"ready","headline":"Harrow terminates $18.4M Melt loan, takes ~47% equity stake; appoints Saharek division president","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Loan Agreement with Melt; received 2.26M Series B-1 and 74k Series B preferred shares in full settlement of ~$18.4M outstanding.","After settlement, Harrow holds ~47% of Melt's equity (including 3.5M common shares) plus royalty rights on Melt drug candidates.","John P. Saharek appointed President/CEO of ImprimisRx division effective Jan 2, 2024; base salary $450K, target bonus 50%.","Melt received FDA support for MELT-300 Phase 3 program; expects to begin Phase 3 in Q1 2024, potentially benefiting Harrow's stake.","Code of Business Conduct and Ethics amended to update corporate name and clarify political activities; no waivers granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259195,"accession_number":"0001493152-23-040555","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow Q3 rev up 50% to $34.3M, cuts FY2023 outlook, targets >$180M in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 rev $34.3M (+50% YoY); GAAP net loss $4.4M; Adjusted EBITDA $9.2M (+270% YoY).","Core gross margin improved to 78% from 72%; cash $65.6M as of Sept 30.","2023 guidance lowered: rev $129-136M, Adj. EBITDA $36-41M; 2024 rev target >$180M excl. TRIESENCE.","IHEEZO launch ahead of internal targets; Fab Five and compounding underperformed.","Completed NDA transfers for five products post-quarter; now selling under Harrow brand."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":93838000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259194,"accession_number":"0001493152-23-039342","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director R. Lawrence Van Horn resigns from Harrow board; board size reduced to four","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Nov 3, 2023, Van Horn resigned immediately; no disagreement with Company operations or policies.","Board size reduced from five to four members.","Perry J. Sternberg appointed to Audit Committee and Nomination and Corporate Governance Committee.","Dr. Martin A. Makary appointed to Compensation Committee and Nomination and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276474,"accession_number":"0001493152-23-034832","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Harrow Health renames to Harrow, Inc., focusing on eyecare pharmaceuticals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from Harrow Health, Inc. to Harrow, Inc. effective September 29, 2023.","Reflects exclusive focus on U.S. ophthalmic pharmaceutical market as part of 5-year strategic plan.","Stockholders not required to approve; rights unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276473,"accession_number":"0001493152-23-027344","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harrow Q2: record revenue $33.5M (+44% YoY), adj. EBITDA $11.0M (+144%); $69M equity offer, product acquisitions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenues of $33.5M, up 44% YoY; GAAP net loss of $4.2M.","Record adjusted EBITDA of $11.0M, up 144% YoY; core gross margin improved to 78% from 73%.","Completed $69M common stock offering and expanded Oaktree loan from $100M to $112.5M.","Acquired North American rights to VEVYE (dry eye drug) and Santen portfolio including FLAREX, NATACYN, TOBRADEX ST.","Reaffirmed 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":59573000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276472,"accession_number":"0001493152-23-025231","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Harrow Health raises $69M in stock offering to fund acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 3,380,282 shares at $17.75/share, initially raising $60M; underwriters later exercised full option for 507,042 additional shares.","Total gross proceeds of $69M after full option exercise; offering closed July 21, 2023.","Net proceeds to fund initial acquisition payment and general corporate purposes, including future product acquisitions.","B. Riley Securities acted as sole book-running manager; Lake Street and Ladenburg Thalmann as co-managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276471,"accession_number":"0001493152-23-024851","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.01","8.01","2.02","7.01","9.01"],"status":"ready","headline":"Harrow acquires VEVYE and Santen ophthalmic rights; Q2 revenue guidance >$31M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired U.S./Canadian rights to VEVYE (cyclosporine 0.1%) from Novaliq; $8M upfront + low double-digit royalties.","Acquired exclusive commercial rights to Santen ophthalmic products; $8M initial payment + milestone/royalty payments.","Preliminary Q2 2023 revenue >$31M (vs $23.3M prior year); Adj EBITDA >$9.3M.","Oaktree credit facility increased to $112.5M; $12.5M draw to fund Santen acquisition.","Proposed underwritten public offering of common stock; B. Riley Securities as book-runner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294208,"accession_number":"0001493152-23-022255","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harrow Health shareholders approve all proposals at 2023 annual meeting; two directors face significant withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five directors elected: Baum, Makary, Sparks, Sternberg, Van Horn; Sparks and Van Horn had ~42% and ~43% of votes cast withheld (8.7M and 9.0M).","KMJ Corbin ratified as auditor for FY2023: 25.4M for, 0.2M against, 28.6K abstain; no broker non-votes.","Advisory say-on-pay approved: 19.7M for, 0.8M against, 0.3M abstain; broker non-votes of 4.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294207,"accession_number":"0001493152-23-016394","cik":1360214,"company_name":"HARROW, INC.","ticker":"HROW","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harrow reports record Q1 revenue of $26.1M, up 18% YoY; reaffirms 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 2023 revenue $26.1M, up 18% YoY vs $22.1M and 28% sequentially (from $20.3M).","Core gross margin 76% vs 75% prior year; adjusted EBITDA $5.3M vs $4.9M.","Reaffirmed FY2023 guidance: net rev $135M-$143M, adj EBITDA $44M-$50M.","Completed NDA transfers for ILEVRO, NEVANAC, MAXIDEX; launched IHEEZO at ASCRS with J-Code.","New $100M credit facility with Oaktree Capital; signed cash-pay agreement with major insurer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":26103000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1310219935.4923031,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-11T23:59:59+00:00|294207"}